Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Living Cell Technologies ( (AU:1AI) ).
Algorae Pharmaceuticals has released a February 2026 non-deal investor presentation outlining general information about the company and its activities, while emphasising that the document is for informational purposes only and does not constitute an offer or solicitation to buy or sell securities. The presentation is framed by extensive disclaimers highlighting the speculative nature of any investment in the company, the confidentiality of the material, the absence of financial product advice, and the inherent risks and uncertainties associated with any statements about future intentions or performance, signalling a cautious approach to investor communications and risk management.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is an ASX-listed pharmaceutical company operating in the life sciences sector, focused on applying advanced science to develop accessible healthcare solutions that support a healthier future. The company targets investors interested in speculative biopharmaceutical opportunities and communicates its activities primarily through ASX announcements and investor presentations.
YTD Price Performance: 50.0%
Average Trading Volume: 2,479,355
Technical Sentiment Signal: Buy
Current Market Cap: A$35.46M
See more insights into 1AI stock on TipRanks’ Stock Analysis page.